Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Acquisition of Argatroban Business in Europe
Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.
Product Name : Arganova
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Anbison
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.
Product Name : Etiasa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Anbison
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Celecoxib
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine
Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...
Product Name : Elyxyb
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : Celecoxib
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethypharm Gains EU Approval for Morphine Immediate Release Tablets
Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Orphelia Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Product Name : Kigabeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Orphelia Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Laboratoires CTRS
Deal Size : Undisclosed
Deal Type : Agreement
Ethypharm, CTRS Partner to Register Orphacol® in China
Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.
Product Name : Orphacol
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2020
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Laboratoires CTRS
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fentanyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Reading Scientific Services
Deal Size : Undisclosed
Deal Type : Partnership
Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients
Details : The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 06, 2020
Lead Product(s) : Fentanyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Reading Scientific Services
Deal Size : Undisclosed
Deal Type : Partnership
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 30, 2013
Lead Product(s) : Baclofen
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2012
Lead Product(s) : Baclofen
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY SERVICES
Reset All
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
